Security
Immuron Limited · IMRN
IMRNNASDAQotherCurrentCIK 1660046Updated Oct 14, 2026
IMRN price & chart
Loading TradingView…
NASDAQ:IMRN on TradingView ↗About the company
Immuron Limited (ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of infectious diseases.
In the news
No coverage from other publishers is available.
Recent filings
Show 5 more recent filings
Financials
FY 2025 · AUDSource
Source
Source
Source
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Profit or LossAUD | -5,215,987Source | -6,936,957Source | -3,786,507Source | -2,854,254Source |
| Additional Financial Items | ||||
| AdjustmentsForFinanceCostsAUD | 7,305Source | 7,576Source | 9,652Source | 6,184Source |
| AdjustmentsForFinanceIncomeAUD | 135,866Source | 327,756Source | 116,323Source | 21,785Source |
| AdjustmentsForSharebasedPaymentsAUD | 304,243Source | 3,299Source | — | — |
| AdjustmentsForUnrealisedForeignExchangeLossesGainsAUD | 12,183Source | -76,771Source | -422,881Source | -234,794Source |
| GeneralAndAdministrativeExpenseAUD | 4,483,623Source | 4,555,726Source | 4,220,905Source | 3,524,388Source |
| IncomeTaxesPaidRefundClassifiedAsOperatingActivitiesAUD | 768,433Source | 395,001Source | — | — |
| InterestPaidClassifiedAsFinancingActivitiesAUD | 7,305Source | 7,576Source | 9,652Source | 6,184Source |
| PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesAUD | 65,661Source | 15,595Source | 35,015Source | 36,264Source |
| ProceedsFromIssuingSharesAUD | — | 24,000Source | — | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cost of Goods and Services Sold | — | — | — | — |
| Total RevenueAUD | 7,287,002Source | 4,902,865Source | 1,804,705Source | 765,193Source |
| Additional Financial Items | ||||
| ApplicableTaxRatenumber | 0.25Source | 0.25Source | 0.25Source | — |
| BasicEarningsLossPerShareAUD/shares | -2.26Source | -3.04Source | -1.66Source | -1.25Source |
| CurrentTaxExpenseIncomeAUD | — | — | -946,627Source | -713,564Source |
| DeferredTaxExpenseIncomeUSD | — | — | 698,195Source | — |
| DeferredTaxExpenseIncomeRecognisedInProfitOrLossAUD | — | — | 698,195Source | — |
| DepreciationAndAmortisationExpenseAUD | — | — | 48,662Source | 42,606Source |
| DepreciationRightofuseAssetsAUD | — | 40,066Source | 41,328Source | 37,937Source |
| DilutedEarningsLossPerShareAUD/shares | -2.26Source | -3.04Source | -1.66Source | -1.25Source |
| EmployeeBenefitsExpenseAUD | 2,120,614Source | — | — | — |
| FinanceCostsAUD | 7,305Source | 7,576Source | 9,652Source | 6,184Source |
| FinanceIncomeAUD | 135,866Source | 327,756Source | 116,323Source | 21,785Source |
| GeneralAndAdministrativeExpenseAUD | 4,483,623Source | 4,555,726Source | 4,220,905Source | 3,524,388Source |
| GrossProfitAUD | 4,765,099Source | 3,336,797Source | 1,309,147Source | 523,502Source |
| InterestExpenseOnLeaseLiabilitiesAUD | — | 7,576Source | 9,652Source | 6,100Source |
| NetForeignExchangeLossAUD | 5,178Source | — | — | — |
| OtherEmployeeExpenseAUD | — | — | 1,874,963Source | 1,212,721Source |
| OtherIncomeAUD | 1,411,505Source | 3,408,199Source | 2,591,498Source | 957,725Source |
| OtherOperatingIncomeExpenseAUD | 30,512Source | 15,760Source | — | — |
| ProfessionalFeesExpenseAUD | 69,068Source | — | — | — |
| ProfitLossAttributableToOwnersOfParentAUD | -5,215,987Source | -6,936,957Source | -3,786,507Source | -2,854,254Source |
| ProfitLossBeforeTaxAUD | -5,215,987Source | -6,936,957Source | -3,786,507Source | -2,854,254Source |
| ProfitLossFromOperatingActivitiesAUD | -5,344,548Source | -5,801,118Source | -3,568,838Source | -2,869,855Source |
| ResearchAndDevelopmentExpenseAUD | 3,597,296Source | 5,375,461Source | 2,592,145Source | 657,715Source |
| SellingExpenseAUD | 481,957Source | — | 192,878Source | 57,854Source |
| ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodAUD | — | -1,456,019Source | -324,340Source | — |
| TaxRateEffectOfForeignTaxRatesnumber | 0.25Source | 0.25Source | 0.25Source | — |
Filing attachments
ea030840601ex99-1.htm · 6-K · 2026-10-13
Exhibit 99.1 Travelan® Phase 2 Study Results Published Melbourne, Australia, October 13, 2026: Immuron Limited (ASX: IMC; NASDAQ: IMRN) today announced that data from its Phase 2 clinical trial of once-daily oral Travelan® has been published in the Nature Journal, Scientific Reports. A copy of the publication can be accessed here: https://doi.org/10.1038/s41598-026-70974-9 The article titled, "A phase 2, randomized, placebo-controlled study to evaluate once-daily oral Travelan for the preven…
Read attachment ↗ea030539801ex4-10.htm · 20-F · 2026-09-24
Exhibit 4.10 CONSULTING AGREEMENT This Consulting Agreement (“Agreement”) is made between Immuron Limited (“Client”) with a principal place of business at Building 10, 25-37 Chapman Street, Blackburn North, VIC 3131, Australia and Pullan Consulting, (“Consultant”), with a principal place of business at 9360 W. Flamingo Rd, Suite 110-554, Las Vegas, Nevada 89147, USA. This agreement will be effective when signed by both parties. Recitals Whereas, Consultant has skills and knowledge in busines…
Read attachment ↗ea030539801ex4-11.htm · 20-F · 2026-09-24
Exhibit 4.11 DISTRIBUTION AGREEMENT This distribution agreement (the “Agreement”) Is entered into on the 2026-09-03 between: Calmino Group AB, reg.no 556638-9820 (SE), Medicinaregatan 8A, 413 46 Gothenburg, Sweden, (the “Supplier”), and Immuron Limited, ABN 80 063 114 045, Unit 10, 25-37 Chapman Street, Blackburn North, VIC 3130, Australia (the “Distributor”). The Supplier and the Distributor are hereinafter also referred to jointly as the “Parties” and individually as a “Party”. …
Read attachment ↗ea030539801ex4-12.htm · 20-F · 2026-09-24
Exhibit 4.12 Option Agreement for Exclusive Sales of PROIBS® in the United States Immuron Limited (IMMURON), a IMMURON having its principal place of business at Building 10, 25-37 Chapman Street, Blackburn North, Victoria 3131, Australia has indicated its interest in having Calmino group AB (CALMINO) Sahlgrenska Science Park, Medicinaregatan 8A, 413 46 Gothenburg, SWEDEN, VAT no.: SE556638982001 enter an exclusive sale, supply distribution and marketing agreement (Distribution Agreement) unde…
Read attachment ↗ea030652901ex99-1.htm · 6-K · 2026-09-24
Exhibit 99.1 Rules 4.7.3 and 4.10.3 Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations Name of entity Immuron Limited ABN/ARBN Financial year ended: 80 30 063 114 045 June 2026 ──────────────────────────────── Our corporate governance statement 1 for the period above can be found at: 2 These pages of our annual report: This www.immuron.com.au/corporate-di…
Read attachment ↗ea030616801ex99-1.htm · 6-K · 2026-09-22
Exhibit 99.1 Immuron CEO, Steven Lydeamore presentation at Coffee Microcaps Conference Melbourne, Australia, September 22, 2026: Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore is presenting at the Coffee Microcaps Conference on Tuesday, 22 September 2026 (2:30pm - 3:00pm Australian Eastern Standard Time) at the State Library of NSW, Sydney. A copy of the presentation made is included below. This release has been authorised by the …
Read attachment ↗